And I'll let Rob talk a little bit more about those details.

Yeah.

So when you think about less than half of the patients that we identified had had their lipid panels done, and then among that cohort where we had follow-up lipids to look at, less than thirty percent is-- twenty-eight percent of them had any sort of lipid-lowering therapy intensification.

So these are the patients that are highest risk, and less than a third of them were getting their lipid-lowering therapy intensified.

Acknowledging that about a third of the patients that had follow-up lipids, their LDLs during follow-up were at goal.

When you factor that in, it still means that nearly forty percent of our, our patients that we had identified did not have lipid-lowering therapy intensification despite being candidates for that intensification.

And that's using the current guideline recommendations at the time.

So even though the medications are no longer considered specialty medications, we still kind of keep it in-house as best as we can in order to identify some of these barriers.

Mm-hmm

... making sure they're on the right meds and getting them off the, perhaps the things that may not be benefiting them.

Um, so th-there, there are a couple different approaches generally speaking.

Um, we speak to the kind of the domain approach a little bit.

There's some, uh, several folks in the cardiovascular community have, have touched on this, particularly as it relates to geriatric care, um, looking at the domain approach.

And then there's been a couple of different frameworks that have been proposed, the four Ms, the five Ms, um, again, that are a little bit more focused towards geriatric care, but I think can be applied, uh, globally, um, to other adults as well as to, uh, children.

Um, you know, care coordination, having a structured approach is certainly, um, one of the biggest things.

But if, if someone's inter-interested in, in doing this, what, what is their process for, for how to, to think about this?